So-Young International (SY) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
31 Aug, 2026Executive summary
Q2 2026 revenue reached RMB 510 million, up 33% year-over-year, setting a quarterly record and exceeding guidance.
Aesthetic treatment services revenue surged 130% year-over-year to RMB 331.4 million, marking the 10th consecutive quarter of triple-digit growth.
Net loss attributable to shareholders narrowed by 37% year-over-year to RMB 22.7 million.
Verified treatment visits and active users more than doubled year-over-year, reflecting robust demand and network expansion.
47 out of 65 branded centers achieved profitability, and 51 generated positive operating cash flow in the quarter.
Financial highlights
Group revenue: RMB 510 million, up 33% year-over-year.
Aesthetic treatment revenue: RMB 331.4 million, up 130% year-over-year.
Gross margin for aesthetic treatment improved by 3.8 percentage points year-over-year to 28.1%.
Basic and diluted loss per ADS: RMB 0.22, improved from RMB 0.35 year-over-year.
Cash and equivalents, including term deposits and short-term investments, stood at RMB 848.2 million as of June 30, 2026.
Outlook and guidance
Q3 2026 revenue from aesthetic treatment services expected between RMB 352 million and RMB 362 million, representing 91.7%-97.2% year-over-year growth.
Management anticipates continued topline growth and a clear path toward profitability as scale and efficiency improve.
Continued focus on transparency, uniform delivery, and accessibility to drive high-quality growth.
Latest events from So-Young International
- Revenue up 45.6% year-over-year, led by aesthetic center growth and new product launches.SY
Q1 2026 - Q4 2025 revenue rose 24.8% YoY as branded centers drove growth and net loss narrowed sharply.SY
Q4 2025 - Aesthetic treatment revenues jumped 305% YoY, but higher costs led to a net loss.SY
Q3 2025 - Aesthetic treatment services revenue soared 426% YoY, now the largest segment, with 50 centers targeted by year-end.SY
Q2 2025 - Q3 revenue exceeded guidance, with strong clinic and medical product growth and higher profitability.SY
Q3 2024 - Q2 revenue beat guidance, profit surged, but Q3 revenue is forecast to decline year over year.SY
Q2 2024 - Goodwill impairment drove a net loss, but aesthetic center revenue grew over 700% year-over-year.SY
Q4 2024 - Branded centers drove a 551% surge in treatment services revenue amid overall revenue decline.SY
Q1 2025